DXSE:XETRA:XETRA-Xtrackers - Stoxx Europe 600 Health Care Swap UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 253.85

Change

+1.75 (+0.69)%

Market Cap

USD 0.14B

Volume

645.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-28 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

+0.08 (+0.17%)

USD 502.95B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

+0.02 (+0.14%)

USD 191.96B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

+0.05 (+0.18%)

USD 177.46B
PRAJ:XETRA Amundi Index Solutions - Amund..

+0.06 (+0.21%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

+0.07 (+0.27%)

USD 157.79B
8R80:XETRA Amundi Index Solutions - Amund..

-1.24 (-0.89%)

USD 102.11B
JARI:XETRA Amundi Index Solutions - Amund..

+0.03 (+0.05%)

USD 102.11B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

+0.08 (+0.16%)

USD 85.64B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

+4.10 (+0.77%)

USD 80.38B
FRCJ:XETRA UBS MSCI Japan Socially Respon..

+0.04 (+0.15%)

USD 79.79B

ETFs Containing DXSE:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 23.32% 96% N/A 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.32% 96% N/A 93% A
Trailing 12 Months  
Capital Gain 21.87% 83% B 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 21.87% 83% B 81% B-
Trailing 5 Years  
Capital Gain 71.47% 82% B 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 71.47% 81% B- 78% C+
Average Annual (5 Year Horizon)  
Capital Gain 8.87% 69% C- 66% D+
Dividend Return 8.87% 68% D+ 64% D
Total Return N/A 11% F 17% F
Risk Return Profile  
Volatility (Standard Deviation) 8.54% 64% D 72% C
Risk Adjusted Return 103.89% 98% N/A 97% N/A
Market Capitalization 0.14B 39% F 35% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.